These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 8960487

  • 1. Use of intravenous gamma-globulin for Kawasaki disease: effects on cardiac sequelae.
    Yanagawa H, Nakamura Y, Sakata K, Yashiro M.
    Pediatr Cardiol; 1997; 18(1):19-23. PubMed ID: 8960487
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Iv gamma globulin treatment of Kawasaki disease in Japan: results of a nationwide survey.
    Yanagawa H, Yashiro M, Nakamura Y, Sakata K, Kawasaki T.
    Acta Paediatr; 1995 Jul; 84(7):765-8. PubMed ID: 7549294
    [Abstract] [Full Text] [Related]

  • 4. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K.
    Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.
    Hsu CH, Chen MR, Hwang FY, Kao HA, Hung HY, Hsu CH.
    Pediatr Infect Dis J; 1993 Jun; 12(6):509-12. PubMed ID: 8345983
    [Abstract] [Full Text] [Related]

  • 6. Kawasaki disease in infants less than one year of age.
    Rosenfeld EA, Corydon KE, Shulman ST.
    J Pediatr; 1995 Apr; 126(4):524-9. PubMed ID: 7699529
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cardiac sequelae of Kawasaki disease in Japan over 10 years.
    Hirose K, Nakamura Y, Yanagawa H.
    Acta Paediatr Jpn; 1995 Dec; 37(6):667-71. PubMed ID: 8775548
    [Abstract] [Full Text] [Related]

  • 9. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
    Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, Yamashita Y, Sugaya A, Komiyama O, Shiro H.
    Arch Dis Child; 2004 Aug; 89(8):776-80. PubMed ID: 15269082
    [Abstract] [Full Text] [Related]

  • 10. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
    Terai M, Shulman ST.
    J Pediatr; 1997 Dec; 131(6):888-93. PubMed ID: 9427895
    [Abstract] [Full Text] [Related]

  • 11. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [Abstract] [Full Text] [Related]

  • 12. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, Iemura M, Ishii M, Kato H.
    Pediatr Int; 1999 Feb; 41(1):1-7. PubMed ID: 10200128
    [Abstract] [Full Text] [Related]

  • 13. Cardiac sequelae of Kawasaki disease in Japan: statistical analysis.
    Nakamura Y, Fujita Y, Nagai M, Yanagawa H, Imada Y, Okawa S, Kawasaki T, Kato H.
    Pediatrics; 1991 Dec; 88(6):1144-7. PubMed ID: 1720235
    [Abstract] [Full Text] [Related]

  • 14. Factors related to cardiac sequelae of Kawasaki disease.
    Zhang T, Yanagawa H, Oki I, Nakamura Y, Yashiro M, Ojima T, Tanihara S.
    Eur J Pediatr; 1999 Sep; 158(9):694-7. PubMed ID: 10485297
    [Abstract] [Full Text] [Related]

  • 15. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.
    Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T.
    Acta Paediatr; 2006 Feb; 95(2):189-93. PubMed ID: 16449025
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of vascular leakage in acute Kawasaki disease.
    Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y.
    Circulation; 2003 Jul 22; 108(3):325-30. PubMed ID: 12835221
    [Abstract] [Full Text] [Related]

  • 17. High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome.
    Kimata H.
    J Allergy Clin Immunol; 1995 Mar 22; 95(3):771-4. PubMed ID: 7897163
    [Abstract] [Full Text] [Related]

  • 18. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease.
    Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, Katoh T, Baba K, Furusho K, Okuni M, Osano M.
    Pediatr Int; 2000 Oct 22; 42(5):464-9. PubMed ID: 11059532
    [Abstract] [Full Text] [Related]

  • 19. Effects of gamma-globulin on the cardiac sequelae of Kawasaki disease.
    Yanagawa H, Tuohong Z, Oki I, Nakamura Y, Yashiro M, Ojima T, Tanihara S.
    Pediatr Cardiol; 1999 Oct 22; 20(4):248-51. PubMed ID: 10368448
    [Abstract] [Full Text] [Related]

  • 20. Predictive risk factors for coronary artery abnormalities in Kawasaki disease.
    Kim T, Choi W, Woo CW, Choi B, Lee J, Lee K, Son C, Lee J.
    Eur J Pediatr; 2007 May 22; 166(5):421-5. PubMed ID: 17033807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.